Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject

A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject

This clinical trial was evaluated to compare the safety and pharmacokinetics of Besylsartan with Amosartan, which was available commercially after single oral dose in healthy male subjects.

Inclusion Criteria:

• Body Mass Index (BMI) between 18 and 30
• Healthy as determined by a responsible physician

Exclusion Criteria:

• History of clinically significant disease
• Any chronic disease
• Creatine clearance less than 50ml/min
• Hypotension (100mmHg/60mmHg)
• Treatment of barbital type drug within 1 month
• Administration of herbal medicine within 7 days